Spyre Therapeutics said Phase 2 data for ulcerative colitis showed proof-of-concept for SPY003 and its broader IBD portfolio. The trial posted 20% clinical remission, 30% endoscopic improvement and a 10-point RHI reduction (p<0.0001).
published
Spyre Therapeutics said Phase 2 data for ulcerative colitis showed proof-of-concept for SPY003 and its broader IBD portfolio. The trial posted 20% clinical remission, 30% endoscopic improvement and a 10-point RHI reduction (p<0.0001).
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.